Skip to main navigation
Alpine Immune Sciences Alpine Immune Sciences

Main navigation

  • About Us
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
    • Contact Us
  • Pipeline & Programs
    • Pipeline
    • ALPN-101
    • ALPN-202
    • ALPN-303
    • Science & Platform
    • Scientific Publications
  • Clinical Trials
  • Investors
    • Stock Information
    • Analyst Coverage
    • News Release
    • Events & Presentations
    • SEC Filings
    • Governance
    • FAQs
    • Investors Contact
  • Careers
  • No menu assigned!

News Releases

Investor Relations - Horizontal

news releases  |  events  |  sec filings  |  governance  | 

board of directors  |  leadership  |  documents  |  committee composition  | 

faqs  |  investors contact  | 
  • Peng
    Read More
    September 1, 2016
    Summary ToggleAlpine Immune Sciences Names Dr. Stanford Peng Executive Vice President and Chief Medical Officer
    Alpine Immune Sciences, Inc. (AIS), a privately held biotechnology company developing a next-generation immune system modulation platform, today announced the appointment of Stanford Peng, M.D., Ph.D., as executive vice president and chief medical officer. In this role, Dr.
    Read More
  • June 13, 2016
    Summary ToggleAlpine Immune Sciences Announces $48 Million Series A Financing to Support Discovery and Development of the Next Generation of Immunotherapies
    Company will leverage its proprietary vIgDTM platform using directed evolution to create novel, multi‐functional first in class immunotherapies SEATTLE, Wash., June 13, 2016 – Alpine Immune Sciences, Inc., (AIS), a privately held biotechnology company developing a next‐generation immune system
    Read More
  • June 1, 2016
    Summary ToggleAlpine pulls in $48 million; tops for a local biotech this year
    A biotechnology company in Seattle led by former Dendreon CEO Mitchell Gold has netted $48 million in funding, marking the region’s largest biotech funding so far this year. Alpine Immune Sciences was formed out of health-care investment fund Alpine BioVentures, also co-founded by Gold.
    Read More
  • June 1, 2016
    Summary ToggleFormer Dendreon CEO Secures $48M For Cancer Immunotherapy Startup
    Mitch Gold will be forever known as the guy who led Dendreon on a controversial roller coaster ride in cancer immunotherapy. Now he’s moved on, and raised a big chunk of money for a startup called Alpine Immune Sciences . Seattle-based Alpine Immune Sciences is announcing today it has raised $48
    Read More
  • June 1, 2016
    Summary ToggleMitch Gold orchestrates $48M round for Alpine’s next-gen immunotherapy play
    Most biotechs go after a launch round and then look for a high-profile industry collaboration. But most biotechs aren’t run by Mitch Gold. The former Dendreon CEO and current venture capitalist has pieced together a $48 million A round for Alpine Immune Sciences in Seattle, which will now look to
    Read More
  • October 27, 2015
    Summary ToggleKite and Alpine Immune Sciences collaborate to improve engineered cellular therapies
    Kite Pharma and Alpine Immune Sciences Announce Research Collaboration and License Agreement to Enhance Immune Response in the Tumor Microenvironment ‐ Kite to Exclusively License Transmembrane Immunomodulatory Protein Technology for Applications to CAR and TCR Programs SANTA MONICA, Calif.
    Read More
  • March 1, 2015
    Summary ToggleWhy ex-Dendreon CEO's new biotech startup could succeed where Dendreon failed
    As former CEO of Seattle biotech Dendreon Corp. Mitchell Gold embarks on a new biotech immunotherapy company called Alpine Immune Sciences Inc. , how will he ensure it doesn’t meet the same fate as his prior company? Gold led Dendreon for nine years and stepped down in 2012.
    Read More
  • February 1, 2015
    Summary ToggleFormer Dendreon CEO launches stealth next-gen immunotherapy startup in Seattle
    Dendreon may be on its last legs , but former CEO Mitchell Gold is happily entrenched in other projects: He’s launching a next-generation immunotherapy startup called Alpine Immune Sciences , seeding about $1.3 million into the company through his investment firm, Alpine BioVentures .
    Read More

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 7
  • Page 8
  • Page 9
  • Current page 10
Displaying 91 - 98 of 98 results

Toolkit

  • Contact Us
  • Email Alerts
  • RSS Feeds
  • Print Page
  • Email Page

Contact

188 East Blaine Street
Suite 200
Seattle, WA
98102
206-788-4545

Sitemap

  • About Us
  • Pipelines & Programs
  • Clinical Trials
  • Investors
  • Careers
  • Contact Us
  • Legal

Twitter

@AlpineImmuneSci

LATEST TWEETS

Tweets by @AlpineImmuneSci

© 2021 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.

Investor Relations - Horizontal

  • News Releases
  • Events
  • SEC Filings
  • Governance
    • Board of Directors
    • Leadership
    • Documents
    • Committee Composition
  • FAQs
  • Investors Contact